Skip to main content

My-O-Den Disease Interactions

There are 3 disease interactions with My-O-Den (adenosine).

Major

Adenosine (applies to My-O-Den) sinus- AV node dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Heart Block, Sinus Node Dysfunction

The use of adenosine is contraindicated in patients with second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia in the absence of a functional artificial pacemaker.

References

  1. Reed R, Falk JL, O'Brien J (1991) "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med, 9, p. 566-70
  2. Engelstein ED, Lerman BB (1993) "Adenosine induced intraatrial block." Pacing Clin Electrophysiol, 16, p. 89-94
  3. (2001) "Product Information. Adenocard (adenosine)." Fujisawa
  4. Kipel G, Rossi AF, Steinberg LG, Gelb B, Fiumecaldo F, Golinko RJ, Griepp RB (1995) "Malignant wide complex tachycardia after adenosine administration to a postoperative pediatric patient with congenital heart disease." Pediatr Cardiol, 16, p. 36-7
View all 4 references
Major

Antiarrhythmics (applies to My-O-Den) cardiovascular dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypotension

Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF). Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk. Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF. Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.

References

  1. Halkin H, Meffin P, Melmon KL, Rowland M (1975) "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther, 17, p. 669-76
  2. Crouthamel WG (1975) "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J, 90, p. 335-9
  3. Ravid S, Podrid PJ, Lampert S, Lown B (1989) "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol, 14, p. 1326-30
  4. Swiryn S, Kim SS (1983) "Quinidine-induced syncope." Arch Intern Med, 143, p. 314-6
  5. Gottlieb SS, Packer M (1989) "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J, 118, p. 611-2
  6. Ochs HR, Grube E, Greenblatt DJ, Arendt R (1981) "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol, 19, p. 173-6
  7. Prescott LF, Adjepon-Yamoah KK, Talbot RG (1976) "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J, 1, p. 939-41
  8. (2002) "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories
  9. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  10. "Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories
  11. "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.
  12. (2001) "Product Information. Adenocard (adenosine)." Fujisawa
  13. (2001) "Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim
  14. Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M (1973) "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med, 78, p. 499-508
  15. Singh SN, Fletcher RD, Fisher SG, et al. (1995) "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med, 333, p. 77-82
  16. (2022) "Product Information. Cordarone (amiodarone)." Apothecon Inc
  17. (2001) "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn
View all 17 references
Moderate

Adenosine (applies to My-O-Den) bronchoconstriction

Moderate Potential Hazard, High plausibility. Applicable conditions: Asthma, Chronic Obstructive Pulmonary Disease

Adenosine induces mast cell degranulation and histamine release. Bronchoconstriction has been reported in patients with asthma during therapy with adenosine. Therapy with adenosine should be administered cautiously in patients with obstructive lung disease not associated with bronchoconstriction (emphysema or bronchitis) and should be avoided in patients with bronchoconstriction or bronchospasm (asthma).

References

  1. (2001) "Product Information. Adenocard (adenosine)." Fujisawa
  2. Aggarwal A, Farber NE, Warltier DC (1993) "Intraoperative bronchospasm caused by adenosine." Anesthesiology, 79, p. 1132-5
  3. Drake I, Routledge PA, Richards R (1994) "Bronchospasm induced by intravenous adenosine." Hum Exp Toxicol, 13, p. 263-5
  4. Ali S, Mustafa SJ, Metzger WJ (1994) "Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine a(1) receptor." J Pharmacol Exp Ther, 268, p. 1328-34
  5. Thorne JR, Broadley KJ (1994) "Adenosine-induced bronchoconstriction in conscious hyperresponsive and sensitized guinea pigs." Am J Respir Crit Care Med, 149, p. 392-9
  6. Bennettguerrero E, Young CC (1994) "Bronchospasm after intravenous adenosine administration." Anesth Analg, 79, p. 386-8
View all 6 references

My-O-Den drug interactions

There are 214 drug interactions with My-O-Den (adenosine).

My-O-Den alcohol/food interactions

There are 3 alcohol/food interactions with My-O-Den (adenosine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer